BeiGene is jumping on the bandwagon for PD-(L)1/CTLA-4 combos ? with a twist.
Through a development and commercialization pact with San Diego-based BioAtla, BeiGene is pairing its PD-1 drug tislelizumab with BA3071, a CTLA-4 blocking ?conditionally active biologic? that gets turned on or off based on whether it?s inside the tumor microenvironment.
San Diego-based BioAtla is responsible for early clinical work, while BeiGene will lead the joint efforts thereafter to develop the combo and deal with regulators around the world. The Chinese biotech, which is committing